Loading cancer entity…
Loading cancer entity…
Clinical trials
115 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03779854 | Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant | active not recruiting | Phase 2 | 45 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03210714 | Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH |
| 2 |
| Sep 22, 2026 |
| clinicaltrials |
| NCT03698994 | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Sep 21, 2026 | clinicaltrials |
| NCT05786924 | Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies | recruiting | Phase 1 / Phase 2 | 554 | Institut de Recherches Internationales ServierOTHER | 10 | Sep 16, 2026 | clinicaltrials |
| NCT04216524 | Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm | recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07819396 | Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome | not yet recruiting | Phase 2 | 52 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03386513 | Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN | active not recruiting | Phase 1 / Phase 2 | 179 | AbbVieINDUSTRY | 6 | Sep 4, 2026 | clinicaltrials |
| NCT07440290 | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07744724 | Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCL | not yet recruiting | Phase 2 | 48 | Changzhou No.2 People's HospitalOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07744737 | Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCL | not yet recruiting | Phase 2 | 34 | Changzhou No.2 People's HospitalOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07744750 | Pirtobrutinib+Sonrotoclax(PS) Regimen in the Treatment of B-Cell Lymphoma | not yet recruiting | Phase 2 | 40 | Changzhou No.2 People's HospitalOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07749365 | Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL | recruiting | Phase 2 | 53 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT04320888 | Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 3 | Aug 3, 2026 | clinicaltrials |
| NCT03155620 | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | active not recruiting | Phase 2 | 1,377 | National Cancer Institute (NCI)NIH | 4 | Jul 24, 2026 | clinicaltrials |
| NCT02523040 | Lenalidomide for Adult Histiocyte Disorders | active not recruiting | Phase 2 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06013423 | Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases | recruiting | Phase 2 | 54 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT04284774 | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 2 | Jul 15, 2026 | clinicaltrials |
| NCT03213652 | Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 4 | Jul 10, 2026 | clinicaltrials |
| NCT07680933 | Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL) | recruiting | Phase 2 | 30 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT04195555 | Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 3 | Jul 1, 2026 | clinicaltrials |
| NCT07007052 | Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients(TAGVEN) | recruiting | Phase 2 | 33 | French Innovative Leukemia OrganisationOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07677813 | Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma | not yet recruiting | Phase 2 | 66 | Ou Bai, MD/PHDOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT03213704 | Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT06411821 | Ulixertinib in People With Histiocytic Neoplasms | recruiting | Phase 2 | 38 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07552324 | Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP | not yet recruiting | Phase 2 | 28 | Ruijin HospitalOTHER | 0 | Apr 27, 2026 | clinicaltrials |
| NCT07288879 | DALY II Japan/MB-CART2019.1 for DLBCL(DALY II Japan) | recruiting | Phase 2 | 31 | Miltenyi Biomedicine GmbHINDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07326371 | Glofitamab Combined With CAR-T Therapy in R/R DLBCL | not yet recruiting | Phase 2 | 24 | Ruijin HospitalOTHER | 0 | Jan 8, 2026 | clinicaltrials |
| NCT07255963 | Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL | recruiting | Phase 2 | 29 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07231250 | Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma | not yet recruiting | Phase 2 | 40 | Li ZhimingOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT04079179 | Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders(NACHO-COBI) | recruiting | Phase 2 | 90 | Carl AllenOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT07034508 | A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1 | not yet recruiting | Phase 2 | 134 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT06891157 | Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes | recruiting | Phase 2 | 148 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 24, 2025 | clinicaltrials |
| NCT06151080 | Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL | recruiting | Phase 2 | 38 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06158399 | AZA Combined With RCHOP in P53-mutated DLBCL. | recruiting | Phase 2 | 52 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT05641428 | Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL(HOVON161) | recruiting | Phase 2 | 300 | University Medical Center GroningenOTHER | 1 | Sep 23, 2024 | clinicaltrials |
Data updated 5 days agoSource updated Sep 25, 2026source: clinicaltrials